Radiotherapy of glioblastoma 15 years after the landmark Stupp’s trial: more controversies than standards?
References
- Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004; 22: 1583-8. 10.1200/JCO.2004.06.082
- Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13: 916-26. 10.1016/S1470-2045(12)70265-6
- Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13: 707-15. 10.1016/S1470-2045(12)70164-X
- Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 2017; 376: 1027-37. 10.1056/NEJMoa1611977
- Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
- Wick W, Platten M, Wick A, Hertenstein A, Radbruch A, Bendszus M, et al. Current status and future directions of anti-angiogenic therapy for gliomas. Neuro Oncol 2016; 18: 315-28. 10.1093/neuonc/nov180
- Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 709-22. 10.1056/NEJMoa1308345
- Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A Randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 699-708. 10.1056/NEJMoa1308573
- Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66. 10.1016/S1470-2045(09)70025-7
- Uhm JH, Porter AB. Treatment of Glioma in the 21st Century: An exciting decade of postsurgical treatment advances in the molecular era. Mayo Clin Proc 2017; 92: 995-1004. 10.1016/j.mayocp.2017.01.010
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96. 10.1056/NEJMoa043330
- Alexander BM, Cloughesy TF. Adult glioblastoma. J Clin Oncol 2017; 35: 2402-09. 10.1200/JCO.2017.73.0119
- Halasz BLM, Soltys SG, Breneman JC, Chan MD, Laack NN, Minniti G, et al. Treatment of gliomas: a changing landscape. Int J Radiat Oncol Biol Phys 2017; 98: 255-8. 10.1016/j.ijrobp.2017.02.223
- Hottinger AF, Pacheco P, Stupp R. Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncol 2016; 18: 1338-49. 10.1093/neuonc/now182
- Mehta M, Wen P, Nishikawa R, Reardon D, Peters K. Critical Reviews in Oncology / Hematology Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncol Hematol 2017; 111: 60-5. 10.1016/j.critrevonc.2017.01.005
- Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma. JAMA 2015; 314: 2535-43. 10.1001/jama.2015.16669
- Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, et al. Effect of Tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA 2017; 318: 2306-16. 10.1001/jama.2017.18718
- Wick W. TTFields: Where does all the skepticism come from? Neuro Oncol 2016; 18: 303-5. 10.1093/neuonc/now012
- Zhu JJ, Demireva P, Kanner AA, Pannullo S, Mehdorn M, Avgeropoulos N, et al. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. J Neurooncol 2017 Aug 28. 10.1007/s11060-017-2601-y. [Epub ahead of print]
- Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 2017; 18: 1373-85. 10.1016/S1470-2045(17)30517-X
- Corso CD, Bindra RS, Mehta MP. The role of radiation in treating glioblastoma: here to stay. J Neurooncol 2017 Mar 7. 10.1007/s11060-016-2348-x. [Epub ahead of print]
- Roth P, Gramatzki D, Weller M. Management of elderly patients with glioblastoma. Curr Neurol Neurosci Rep 2017; 17: 35. 10.1007/s11910-017-0740-3
- Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5: 1725-31. 10.1016/0360-3016(79)90553-4
- Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983; 52:997-1007.
- Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002; 20: 1635-42.
- Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002; 51: 343-57.
- Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004; 60: 853-60. 10.1016/j.ijrobp.2004.04.011
- Werner-Wasik M, Scott CB, Nelson DF, Gaspar LE, Murray KJ, Fischbach JA, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer 1996; 77: 1535-43.
- Badiyan SN, Markovina S, Simpson JR, Robinson CG, DeWees T, Tran DD, et al. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide. Int J Radiat Oncol Biol Phys 2014; 90: 877-85. 10.1016/j.ijrobp.2014.07.014
- Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA KD. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987; 62: 450-9.
- Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol 2016; 18: 426-34. 10.1093/neuonc/nov148
- Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 2016; 18: 1199-208. 10.1093/neuonc/now058
- Whitfield GA, Kennedy SR, Djoukhadar IK, Jackson A. Imaging and target volume delineation in glioma. Clin Oncol (R Coll Radiol) 2014; 26: 364-76. 10.1016/j.clon.2014.04.026
- Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, et al. Biopsy validation of 18 F-DOPA PET and planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol 2013; 15: 1058-67. 10.1093/neuonc/not002
- Mills SJ, Du Plessis D, Pal P, Thompson G, Buonacorrsi G, Soh C, et al. Mitotic activity in glioblastoma correlates with estimated extravascular extracellular space derived from dynamic contrast-enhanced MR imaging. Am J Neuroradiol 2016; 37: 811-7. 10.3174/ajnr.A4623
- Brindle KM, Izquierdo-García JL, Lewis DY, Mair RJ, Wright AJ. Brain tumor imaging. J Clin Oncol 2017; 35: 2432-8. 10.1200/JCO.2017.72.7636
- Niyazi M, Geisler J, Siefert A, Schwarz SB, Ganswindt U, Garny S, et al. FET-PET for malignant glioma treatment planning. Radiother Oncol 2011; 99: 44-8. 10.1016/j.radonc.2011.03.001
- Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, et al. Radiation therapy for glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. J Clin Oncol 2017; 35: 361-9. 10.1200/JCO.2016.70.7562
- Niyazi M, Brada M, Chalmers AJ, Combs SE, Erridge SC, Fiorentino A, et al. ESTRO-ACROP guideline “target delineation of glioblastomas.” Radiother Oncol 2016; 118: 35-42. 10.1016/j.radonc.2015.12.003
- Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 2010; 97: 377-81. 10.1016/j.radonc.2010.08.020
- Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella D, Webster B, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131:803-20. 10.1007/s00401-016-1545-1
- Chan MF, Schupak K, Burman C, Chui C-S, Ling CC. Comparison of intensity-modulated radiotherapy with three-dimensional conformal radiation therapy planning for glioblastoma multiforme. Med Dosim 2003; 28:261-5. 10.1016/j.meddos.2003.08.004
- Panet-Raymond V, Souhami L, Roberge D, Kavan P, Shakibnia L, Muanza T, et al. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys 2009; 73: 473-8. 10.1016/j.ijrobp.2008.04.030
- Shenouda G, Souhami L, Petrecca K, Owen S, Panet-Raymond V, Guiot M-C, et al. A phase 2 trial of neoadjuvant temozolomide followed by hypofractionated accelerated radiation therapy with concurrent and adjuvant temozolomide for patients with glioblastoma. Int J Radiat Oncol Biol Phys 2017; 97: 487-94. 10.1016/j.ijrobp.2016.11.006
- Ataman F, Poortmans P, Stupp R, Fisher B, Mirimanoff RO. Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. Eur J Cancer 2004; 40: 1724-30. 10.1016/j.ejca.2004.03.026
- Kazda T, Jancalek R, Pospisil P, Sevela O, Prochazka T, Vrzal M, et al. Why and how to spare the hippocampus during brain radiotherapy: the developing role of hippocampal avoidance in cranial radiotherapy. Radiat Oncol 2014; 9: 139. 10.1186/1748-717X-9-139
- Gondi V, Hermann BP, Mehta MP, Tomé WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys 2013; 85: 348-54. 10.1016/j.ijrobp.2012.11.031
- Gzell C, Back M, Wheeler H, Bailey D, Foote M. Radiotherapy in glioblastoma: the past, the present and the future. Clin Oncol (R Coll Radiol) 2017; 29: 15-25. 10.1016/j.clon.2016.09.015
- Smith AW, Mehta MP, Wernicke AG. Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma. J Neurooncol 2016; 128: 1-10. 10.1007/s11060-016-2123-z
- Chen L, Chaichana KL, Kleinberg L, Ye X, Quinones-Hinojosa A, Redmond K. Glioblastoma recurrence patterns near neural stem cell regions. Radiother Oncol 2015; 116: 294-300. 10.1016/j.radonc.2015.07.032
- Khalifa J, Tensaouti F, Lusque A, Plas B, Lotterie J-A, Benouaich-Amiel A, et al. Subventricular zones: new key targets for glioblastoma treatment. Radiat Oncol 2017; 12: 67. 10.1186/s13014-017-0791-2
- Nourallah B, Digpal R, Jena R, Watts C. Irradiating the subventricular zone in glioblastoma patients: is there a case for a clinical trial? Clin Oncol (R Coll Radiol) 2017; 29: 26-33. 10.1016/j.clon.2016.09.005
- Pospisil P, Kazda T, Hynkova L, Bulik M, Dobiaskova M, Burkon P, et al. Post-WBRT cognitive impairment and hippocampal neuronal depletion measured by in vivo metabolic MR spectroscopy: results of prospective investigational study. Radiother Oncol 2017; 122: 373-9. 10.1016/j.radonc.2016.12.013
- Flechl B, Sax C, Ackerl M, Crevenna R, Woehrer A, Hainfellner J, et al. The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma. Radiother Oncol 2017; 125: 228-33. 10.1016/j.radonc.2017.07.027
- Weller M, Roth P, Preusser M, Wick W, Reardon DA, Platten M, et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol 2017; 13: 363-74. 10.1038/nrneurol.2017.64
- Sampson JH, Maus MV, June CH. Immunotherapy for brain tumors. J Clin Oncol 2017; 35: 2450-6. 10.1200/JCO.2017.72.8089
- Reznik E, Smith AW, Taube S, Mann J, Yondorf MZ, Parashar B, et al. Radiation and immunotherapy in high-grade gliomas. Am J Clin Oncol 2017 Sep 12. 10.1097/COC.0000000000000406. [Epub ahead of print]
Language: English
Page range: 121 - 128
Submitted on: Nov 7, 2017
Accepted on: Mar 12, 2018
Published on: Jun 6, 2018
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2018 Tomas Kazda, Adam Dziacky, Petr Burkon, Petr Pospisil, Marek Slavik, Zdenek Rehak, Radim Jancalek, Pavel Slampa, Ondrej Slaby, Radek Lakomy, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.